



www.genfit.com

**GENFIT: CONVERSION OF 30 OCA2012-2 BONDS  
AND ISSUE OF NEW SHARES FOLLOWING THE  
IMPLEMENTATION OF THE SEVENTH INSTALLMENT  
OF THE RESERVED CONVERTIBLE BOND LOAN  
AGREEMENT OF €8 M**

- **30 of the 100 OCA2012-2 bonds issued upon the implementation of the sixth installment of the bond loan agreement converted into shares by the Bondholder.**
- **Issue of 8197 new shares corresponding to the payment in shares of the commitment fee of the seventh installment of the bond loan agreement.**

**Lille (France), Boston (Massachusetts, United States), April 9, 2013** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it has issued 8197 new shares corresponding to the payment in shares of the commitment fee of the seventh €1 M installment of the convertible bond loan agreement of €8 M signed on December 20th, 2012, as well as the conversion into shares of 30 of the 100 bonds of the sixth installment, in keeping with the 1<sup>st</sup> and 2<sup>nd</sup> resolutions of the Extraordinary Shareholders' Meeting of December 18th, 2012 ("the Assembly").

In keeping with these resolutions, with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), and with the decision of GENFIT's Management Board to implement the seventh installment of €1 M, a commitment fee of approximately 5% of the value of this new installment (€50,000), has been paid to the Bondholder in ordinary Company shares with an issue price of €6.10, issue premium included, in keeping with the second resolution of the Assembly, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (March 28 – April 5, 2013) prior to the decision to pay this commitment fee. As a result, 8197 new shares immediately assimilated with existing shares have been subscribed by the Bondholder to offset this commitment fee.

In keeping with the 1<sup>st</sup> and 2<sup>nd</sup> resolutions of the Assembly and with the convertible loan contract, the Bondholder made one conversion request on April 5, 2013 of 10 OCA2012-2 bonds, and one further conversion request on April 8, 2013 of 20 OCA2012-2 bonds, all corresponding to the sixth installment.

The conversion of 10 OCA2012-2 bonds on April 5, 2013 into 16,730 new shares was performed at a conversion rate of €5.98, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (March 27 – April 4, 2013) prior to the conversion request.

The conversion of 20 OCA2012-2 bonds on April 8, 2013 into 32,803 new shares was performed at a conversion rate of €6.10, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (March 28 – April 5, 2013) prior to the conversion request.

As a result of these conversions and reserved share issues to the Bondholder:

- The social capital of GENFIT has increased from €4,328,556 to €4,342,988.50;
- The number of shares representing the social capital of GENFIT has increased by 57,730, from 17,314,224 to 17,371,954 shares;
- The amount of the sixth installment of the bond loan agreement that remains to be converted is €200,000.

**About GENFIT:**

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

**Contacts:**

**GENFIT**

Jean-François Mouney – CEO & Chairman of the Management Board  
Ph. +333 2016 4000

**MILESTONES – Press Relations**

Bruno Arabian  
Ph. +331 7544 8740 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)